Human CellExp™ Glypican 3 / GPC3, Human recombinant | P1057

Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function.

P1057 | Human CellExp Glypican 3 / GPC3 Human recombinant DataSheet

Biomolecule/Target: GPC3

Synonyms: Glypican-3, GTR2-2, Intestinal protein OCI-5, MXR7, GPC3, OCI5

Alternates names: Protein arginine N-methyltransferase 1, Histone-arginine N-methyltransferase PRMT1, Interferon receptor 1-bound protein 4, Histone-arginine N-methyltransferase PRMT1, Interferon receptor 1-bound protein 4

Taglines: Cell surface proteoglycan that inhibits the dipeptidyl peptidase activity of DPP4 and involved in modulation of IGF2 interactions with its receptor.

NCBI Gene ID #: 3276

NCBI Gene Symbol: ANM1

Gene Source: Human

Accession #: Q99873

Recombinant: Yes

Source: E. coli

Purity by SDS-PAGEs: 90%

Assay: SDS-PAGE

Purity: N/A

Assay #2: N/A

Endotoxin Level: N/A

Activity (Specifications/test method): Measured by its binding ability in a functional ELISA.

Biological activity: N/A

Results: N/A

Binding Capacity: Measured by its binding ability with FGF-2 in a functional ELISA. Human Glypican 3 (Cat. No. P1057) can bind Immobilized FGF-2 (Cat. No. 4037 at 0.05 g/well) with a linear range of 2.5-600 ng/mL.

Unit Definition: N/A

Molecular Weight: 84.0 kDa

Concentration: N/A

Appearance: Lyophilized

Physical form description: Lyophilized from 0.22 m filtered solution in PBS, pH7.4 with 5% Trehalose added as protectant before lyophilization.

Reconstitution Instructions: N/A

Amino acid sequence: MHHHHHHMKI EEGKLVIWIN GDKGYNGLAE VGKKFEKDTG IKVTVEHPDK LEEKFPQVAA TGDGPDIIFW AHDRFGGYAQ SGLLAEITPD KAFQDKLYPF TWDAVRYNGK LIAYPIAVEA LSLIYNKDLL PNPPKTWEEI PALDKELKAK GKSALMFNLQ EPYFTWPLIA ADGGYAFKYE NGKYDIKDVG VDNAGAKAGL TFLVDLIKNK HMNADTDYSI AEAAFNKGET AMTINGPWAW SNIDTSKVNY GVTVLPTFKG QPSKPFVGVL SAGINAASPN KELAKEFLEN YLLTDEGLEA VNKDKPLGAV ALKSYEEELA KDPRIAATME NAQKGEIMPN IPQMSAFWYA VRTAVINAAS GRQTVDEALK DAQTNSSSNN NNNNNNNNLG IEGRGSHMAA AEAANCIMEV SCGQAESSEKPNAEDMTSKD YYFDSYAHFG IHEEMLKDEV RTLTYRNSMF HNRHLFKDKV VLDVGSGTGI LCMFAAKAGA RKVIGIECSS ISDYAVKIVK ANKLDHVVTI IKGKVEEVEL PVEKVDIIIS EWMGYCLFYE SMLNTVLYAR DKWLAPDGLI FPDRATLYVT AIEDRQYKDY KIHWWENVYG FDMSCIKDVA IKEPLVDVVD PKQLVTNACL IKEVDIYTVK VEDLTFTSPF CLQVKRNDYV HALVAYFNIE FTRCHKRTGF STSPESPYTH WKQTVFYMED YLTVKTGEEI FGTIGMRPNA KNNRDLDFTI DLDFKGQLCE LSCSTDYRMR.